Current treatment for hepatitis C virus/human immunodeficiency virus coinfection in adults

Table 1 Prevalence and sustained virologic response after hepatitis C virus treatment in patients with hepatitis C virus monoinfection compared to patients with hepatitis C virus/human immunodeficiency virus coinfection

	HCV monoinfection	HCV/HIV coinfection
Prevalence	184 million person worldwide	2.3 million person worldwide
SVR after interferon treatment	36%-76% (genotype 1, 2, 3, 4, treatment naïve)	18.4%-50% (genotype 1, 2, 3, 4, treatment naïve)
SVR after DAA treatment	96%-100% (pangenotype, treatment naïve)	95%-98% (pangenotype, treatment naïve)

DAA: Direct-acting antiviral; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; SVR: Sustained virologic response.

Table 2 Drug-drug interaction between antiretroviral drugs and direct-acting antiviral agents

Antiretroviral drugs	SOF/LED	SOF/VEL	SOF/VEL/VOX	EBR/GZR	GLE/PIB
NRTIs
Tenoforvir disoproxil fumarate	▲	▲	▲	-	-
NNRTIs
Efavarenz	-	X	X	X	X
Etravirenz	-	X	X	X	X
Nevirapine	-	X	X	X	X
Protease inhibitors
Atazanavir/ritonavir	-	-	X	X	X
Atazanavir/cobicistat	-	-	X	X	X
Darunavir/ritonavir	-	-	X	X	X
Darunavir/cobicistat	-	-	-	X	X
Lopinavir/ritonavir	-	-	X	X	X

▲: Should be avoided in patients with an eGFR < 60 mL/min; X: Should be avoided; EBR: Elbasvir; GLE: Glecaprevir; GZR: Grazoprevir; LDV: Ledipasvir; NNRTIs: Non-nucleoside reverse transcriptase inhibitors; NRTIs: Nucleoside reverse transcriptase inhibitors; PIB: Pibrentasvir; SOF: Sofosbuvir; VEL: Velpatasvir; VOX: Voxilaprevir.